X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals develops and commercializes therapies for rare diseases of the immune system, with a focus on rare hematology conditions and significant unmet needs. Its expertise includes immune-system and CXCR4 biology. The company developed mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI for WHIM syndrome, and is advancing it in a global Phase 3 trial for chronic neutropenic disorders, while evaluating additional patient populations.